

## Special Issue

# Antimicrobial Resistance and Virulence – 3rd Volume

### Message from the Guest Editors

The use of antibiotics for the treatment of infectious diseases began in the 1940s with penicillin. In spite of their unquestionable contribution to the decline of morbidity and mortality rates in both human and veterinary medicine, antibiotics administration prompted the emergence and dissemination of multiresistant bacterial strains. In 2017, the World Health Organization (WHO) has published a list of antimicrobial-resistant "priority pathogens" for which new therapeutic solutions are urgent, which include a group of microorganisms with high level resistance to multiple drugs, named ESKAPE pathogens. These bacteria also have the ability to produce several virulence factors, which have a major influence on infectious disease outcome. In fact, some virulence factors, such as biofilm-producing ability and others, contribute to an increased resistance ability. This Special Issue constitutes a Third Volume focusing on Antimicrobial Resistance and Virulence, and aims to publish manuscripts that further clarify on the impact of bacterial antimicrobial resistance and virulence in the three areas of the One Health triad, i.e., animal, human, and environmental health.

### Guest Editors

Dr. Manuela Oliveira

1. Centre for Interdisciplinary Research in Animal Health (CIISA), Faculty of Veterinary Medicine, University of Lisbon, 1300-477 Lisboa, Portugal
2. Associate Laboratory for Animal and Veterinary Sciences (AL4AnimalS), 1300-477 Lisboa, Portugal
3. Centre for Ecology, Evolution and Environmental Changes (cE3c) & Global Change and Sustainability Institute (CHANGE), Faculty of Sciences, University of Lisbon, Campo Grande, 1749-016 Lisboa, Portugal

Dr. Elisabete Silva

CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine of Lisbon, Lisboa, Portugal

### Deadline for manuscript submissions

closed (31 March 2023)



## Antibiotics

an Open Access Journal  
by MDPI

Impact Factor 4.3  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/si/108022](https://mdpi.com/si/108022)

*Antibiotics*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.3  
CiteScore 7.3  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1  
(General Pharmacology, Toxicology and Pharmaceutics)